

Cover Story
ECOG-ACRIN Cancer Research Group is starting enrollment in NCI-MATCH, the most ambitious of NCI's new generation of clinical trials.
In Brief
Trending Stories
- How George Tidmarsh crossed the FDA-industry Rubicon
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval - Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership
- City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
- Mary Pazdur, 63, Dies of Cancer; What Her Husband Has Learned











